We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline can... Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma. Show more
SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the โCompanyโ), a biotechnology company focused on innovating, developing, and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.935 | -14.8731744812 | 13.01 | 13.13 | 11.045 | 4551577 | 11.949459 | CS |
4 | -4.159 | -27.3007745832 | 15.234 | 15.5 | 11.045 | 4482067 | 13.34011213 | CS |
12 | 3.375 | 43.8311688312 | 7.7 | 18.33 | 7.34 | 9324703 | 13.71952369 | CS |
26 | 7.785 | 236.626139818 | 3.29 | 18.33 | 3.21 | 8375361 | 10.26260287 | CS |
52 | 5.455 | 97.0640569395 | 5.62 | 18.33 | 3.21 | 7131437 | 8.76429926 | CS |
156 | -18.525 | -62.5844594595 | 29.6 | 33.55 | 3.21 | 4443324 | 10.72574569 | CS |
260 | 0.025 | 0.226244343891 | 11.05 | 54.2081 | 3.21 | 3293686 | 14.32640185 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions